Today: 30 June 2026
KLA stock dips today as peers climb; guidance and China export rules keep traders cautious
2 February 2026
1 min read

KLA stock dips today as peers climb; guidance and China export rules keep traders cautious

New York, February 2, 2026, 11:08 (EST) — Regular session

KLA Corporation shares slipped roughly 1% to $1,414 in late morning trading, underperforming other chip-equipment stocks like Applied Materials, Lam Research, and ASML Holding. Both the iShares Semiconductor ETF and VanEck Semiconductor ETF climbed, while the broader market also pushed higher.

The divergence is significant since KLA’s inspection and measurement tools are embedded deep in the chip production process, making its guidance a key indicator of chipmakers’ manufacturing equipment spending this year. Given stretched valuations in parts of the sector, even slight changes in outlook have been driving individual stocks more than the broader group.

Following last week’s earnings, KLA’s stock dipped in after-hours trading despite beating estimates. Michael Ashley Schulman, chief investment officer at Running Point Capital Advisors, described the March quarter as showing steady growth rather than a clear acceleration. He also pointed to lingering doubts about demand from China and the impact of U.S. export controls, even as some peers have sounded a more optimistic note in recent reports.

KLA reported second-quarter revenue of $3.30 billion, with adjusted, or non-GAAP, earnings coming in at $8.85 per share. Looking ahead to the March quarter, it projects revenue around $3.35 billion, plus or minus $150 million, and non-GAAP EPS near $9.08, give or take 78 cents. CEO Rick Wallace highlighted a “record quarter for revenue and free cash flow,” driven by strong demand linked to advanced chipmaking. KLA Corporation

Non-GAAP results exclude certain items the company considers outside its core operations. Investors keep a close eye on this metric in chip equipment, where margins often fluctuate due to supply mix, rushed shipping, and component expenses.

They’re digging into KLA’s outlook on wafer-fab equipment spending — the gear for chip production — as makers ramp up capacity for advanced processors and memory. Timing is crucial here. Even a slight delay of a few weeks in deliveries or installations can push revenue into different quarters.

However, the company flagged potential hurdles in its quarterly filing, noting that export-control rules from the U.S. Department of Commerce’s Bureau of Industry and Security might limit sales of some products and services to Chinese customers. KLA also highlighted risks tied to disruptions among third-party suppliers and warned that rising DRAM prices for its image computers could pressure gross margins.

Traders are keeping an eye on how order sentiment stabilizes following the earnings surge, along with any weekly shifts in discussions about export licenses and supply chains. Changes in those areas usually hit the high-multiple equipment stocks quickly.

KLA’s earnings for the March quarter are due next, with Investing.com marking the date as April 23.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs
Previous Story

Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs

Johnson & Johnson stock rises as new Erleada survival data lands
Next Story

Johnson & Johnson stock rises as new Erleada survival data lands

Go toTop